Intestinal complications in Brazilian patients with ulcerative colitis treated with conventional therapy between 2011 and 2020

Table 2 Demographic characteristics and follow-up of patients with ulcerative colitis treated with conventional therapies, n (%)

Variable	n	%
Patients	41229	100
Age1, yr
mean ± SD	48.86 ± 15.42
Median (IQI)	48.09 (60.15-36.94)
Sex
Male	14417	35
Female	26812	65
Ethnicity
White	23290	56
Black and other	11987	33
Missing	4643	11
CVT initiation
2011	4300	10
2012	4054	10
2013	4259	10
2014	4877	12
2015	4846	12
2016	5039	12
2017	5565	13
2018	5040	12
2019	3249	8
Follow-up time2, yr
mean ± SD	3.65 (2.27)
Median (IQI)	3.25 (1.75-5.26)
Region of residence
Southeast	22942	56
South	8831	21
Midwest	2638	6
Northeast	5833	14
North	985	2
Missing	0	0
Patients under CVT
Mesalazine	35923	87
Sulfasalazine	6148	15
Azathioprine	6413	16
Ciclosporine	116	0
Methotrexate	290	1
Time using CVT3, yr
mean ± SD	2.64 (2.29)
Median (IQI)	1.92 (0.75-4.00)
Patients switched treatment after first IC4	2564	6
Time to switch treatment after IC, yr
mean ± SD	0.36 (0.76)
Median (IQI)	0.08 (0.08-0.25)
Min	0.08

Values are expressed as numbers (%) or medians (range).

¹Age at index date.

²Time since index date up to the last date of patient information available in the database.

³Calculated based on the index date and the last claim of conventional therapy.

⁴Switching from one conventional therapy to another conventional therapy.

CVT: Conventional therapy; IQI: Interquartile interval; UC: Ulcerative colitis.